

Merchant & Gould

An Intellectual Property Law Firm

RECEIVED
CENTRAL FAX CENTER

OCT 26 2004

3200 IDS Center
80 South Eighth Street
Minneapolis, Minnesota
55402-2215 USA
TEL 612.332.5300
FAX 612.332.9081
www.merchant-
gould.com

A Professional Corporation

Fax Transmission | October 26, 2004

TO: Commissioner for Patents
Attn: Examiner Robert Clinton Hayes
P.O. Box 1450
Alexandria, VA 22313-1450

FROM: Eric DeMaster

OUR REF: 9548.50USWO
TELEPHONE: 612.336.4638


Total pages, including cover letter: 13

PTO FAX NUMBER 1-703-872-9306

If you do NOT receive all of the pages, please telephone us at 612.336.4638, or fax us at 612.332.9081.


Title of Document Transmitted: AMENDMENT AND RESPONSE
Applicant: LONG YU
Serial No.: 09/787328
Filed: March 16, 2001
Group Art Unit: 1647
Our Ref. No.: 9548.50USWO
Confirmation: 9496

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: Eric DeMaster
Reg. No.: 55,107

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Lynnda Kraft


Signature

Oct. 26, 2004
Date

**RECEIVED
CENTRAL FAX CENTER**

S/N 09/787328

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Long Yu Examiner: Robert Clinton Hayes
Serial No.: 09/787328 Group Art Unit: 1647
Filed: March 16, 2001 Docket No.: 9548.50USWO
Title: NEW HUMAN HEPATOMA-DERIVED GROWTH FACTOR ENCODING
SEQUENCE AND POLYPEPTIDE ENCODED BY SUCH DNA
SEQUENCE AND PRODUCING METHOD THEREOF

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on October 26, 2004.

By: 

Name: Lynnda Kraft

AMENDMENT AND RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed July 26, 2004, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.

Amendments to the Abstract begin on page 5 of this paper.

Amendments to the Drawings begin on page 6 of this paper and include both an attached replacement sheet and an annotated sheet showing changes.

Remarks begin on page 7 of this paper.